554 related articles for article (PubMed ID: 25597784)
1. Targeting drivers of melanoma with synthetic small molecules and phytochemicals.
Strickland LR; Pal HC; Elmets CA; Afaq F
Cancer Lett; 2015 Apr; 359(1):20-35. PubMed ID: 25597784
[TBL] [Abstract][Full Text] [Related]
2. Advances in targeted therapy for unresectable melanoma: new drugs and combinations.
Hao M; Song F; Du X; Wang G; Yang Y; Chen K; Yang J
Cancer Lett; 2015 Apr; 359(1):1-8. PubMed ID: 25578781
[TBL] [Abstract][Full Text] [Related]
3. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
[TBL] [Abstract][Full Text] [Related]
4. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
[TBL] [Abstract][Full Text] [Related]
5. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
6. Prospects for non-immunological molecular therapeutics in melanoma.
Eustace AJ; Mahgoub T; Tryfonopoulos D; O'Donovan N; Crown J
J BUON; 2010; 15(1):9-18. PubMed ID: 20414921
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-PeƱas P
JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
[TBL] [Abstract][Full Text] [Related]
8. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
9. MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy.
Tran KA; Cheng MY; Mitra A; Ogawa H; Shi VY; Olney LP; Kloxin AM; Maverakis E
Drug Des Devel Ther; 2016; 10():43-52. PubMed ID: 26730180
[TBL] [Abstract][Full Text] [Related]
10. A new standard of care for metastatic melanoma?
Sharma SP
Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559
[No Abstract] [Full Text] [Related]
11. Trametinib (GSK1120212) in the treatment of melanoma.
Salama AK; Kim KB
Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
[TBL] [Abstract][Full Text] [Related]
12. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
13. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
14. BRAF and MEK inhibition in melanoma.
Dossett LA; Kudchadkar RR; Zager JS
Expert Opin Drug Saf; 2015 Apr; 14(4):559-70. PubMed ID: 25648338
[TBL] [Abstract][Full Text] [Related]
15. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.
Simeone E; Grimaldi AM; Festino L; Vanella V; Palla M; Ascierto PA
BioDrugs; 2017 Feb; 31(1):51-61. PubMed ID: 28058658
[TBL] [Abstract][Full Text] [Related]
16. MEK inhibitors for the treatment of NRAS mutant melanoma.
Sarkisian S; Davar D
Drug Des Devel Ther; 2018; 12():2553-2565. PubMed ID: 30154648
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):221-36; quiz 237-8. PubMed ID: 25592339
[TBL] [Abstract][Full Text] [Related]
18. Dabrafenib in combination with trametinib for the treatment of metastatic melanoma.
Awad MM; Sullivan RJ
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):25-33. PubMed ID: 25473943
[TBL] [Abstract][Full Text] [Related]
19. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
[TBL] [Abstract][Full Text] [Related]
20. BRAF inhibitors in cancer therapy.
Hertzman Johansson C; Egyhazi Brage S
Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]